Literature DB >> 31074794

Clinical utility of the 2016 ASE/EACVI recommendations for the evaluation of left ventricular diastolic function in the stratification of post-discharge prognosis in patients with acute heart failure.

Tomoko Machino-Ohtsuka1, Yoshihiro Seo1, Tomoko Ishizu1, Yoshie Hamada-Harimura1, Masayoshi Yamamoto1, Kimi Sato1, Seika Sai1, Akinori Sugano2, Kenichi Obara3, Ikuo Yoshida4, Isao Nishi5, Kazutaka Aonuma1, Masaki Ieda1.   

Abstract

AIMS: Left ventricular diastolic dysfunction (LVDD) has prognostic significance in heart failure (HF). We aimed to assess the impact of LVDD grade stratified by the updated 2016 echocardiographic algorithm (DD2016) on post-discharge outcomes in patients admitted for acute HF and compare with the previous 2009 algorithm (DD2009). METHODS AND
RESULTS: The study included 481 patients hospitalized for acute decompensated HF. Comprehensive echocardiography and LVDD evaluation were performed just before hospital discharge. The primary endpoint was a composite of cardiovascular death and readmission for HF. The concordance between DD2016 and DD2009 was moderate (κ = 0.44, P < 0.001); the reclassification rate was 39%. During the follow-up (median: 15 months), 127 (26%) patients experienced the primary endpoint. In the Kaplan-Meier analysis, Grade III in DD2016 showed a lower event-free survival rate than Grades I and II (log rank, P < 0.001 and P = 0.048, respectively) and was independently associated with a higher incidence of the primary endpoint than Grade I [hazard ratio 1.89; 95% confidence interval (CI) 1.17-3.04; P = 0.009]. Grade II or III in DD2016, reflecting elevation of left ventricular (LV) filling pressure, added an incremental predictive value of the primary endpoint to clinical variables irrespective of LV ejection fraction. DD2016 was comparable to DD2009 in predicting the endpoint (net reclassification improvement = 11%; 95% CI -7% to 30%, P = 0.23).
CONCLUSION: Despite simplification of the algorithm for LVDD evaluation, the prognostic value of DD2016 for post-discharge cardiovascular events in HF patients was maintained and not compromised in comparison with DD2009. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  echocardiography; heart failure; left ventricular diastolic dysfunction; prognosis

Mesh:

Year:  2019        PMID: 31074794     DOI: 10.1093/ehjci/jez082

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  4 in total

1.  Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.

Authors:  Benedetta Maria Bonora; Saula Vigili de Kreutzenberg; Angelo Avogaro; Gian Paolo Fadini
Journal:  Cardiovasc Diabetol       Date:  2019-08-14       Impact factor: 9.951

2.  Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience.

Authors:  Michael M Hammond; Changyu Shen; Stephanie Li; Dhruv S Kazi; Marwa A Sabe; A Reshad Garan; Lawrence J Markson; Warren J Manning; Allan L Klein; Sherif F Nagueh; Jordan B Strom
Journal:  PLoS One       Date:  2020-12-22       Impact factor: 3.240

3.  Visual echocardiographic scoring system of the left ventricular filling pressure and outcomes of heart failure with preserved ejection fraction.

Authors:  Michito Murayama; Hiroyuki Iwano; Masaru Obokata; Tomonari Harada; Kazunori Omote; Kazuki Kagami; Shingo Tsujinaga; Yasuyuki Chiba; Suguru Ishizaka; Ko Motoi; Yoji Tamaki; Hiroyuki Aoyagi; Masahiro Nakabachi; Hisao Nishino; Shinobu Yokoyama; Asuka Tanemura; Kazunori Okada; Sanae Kaga; Mutsumi Nishida; Toshiyuki Nagai; Masahiko Kurabayashi; Toshihisa Anzai
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-04-18       Impact factor: 9.130

4.  Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling.

Authors:  Seul-Gee Lee; Darae Kim; Jung-Jae Lee; Hyun-Ju Lee; Ro-Kyung Moon; Yong-Joon Lee; Seung-Jun Lee; Oh-Hyun Lee; Choongki Kim; Jaewon Oh; Chan Joo Lee; Yong-Ho Lee; Seil Park; Ok-Hee Jeon; Donghoon Choi; Geu-Ru Hong; Jung-Sun Kim
Journal:  BMC Med       Date:  2022-09-07       Impact factor: 11.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.